Is AKBA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for AKBA. It does not provide personalized investment advice.

AKBA (Akebia Therapeutics, Inc.) Stock Analysis - Financials

Akebia Therapeutics, Inc. (AKBA) is a publicly traded Healthcare sector company. As of September 14, 2026, AKBA trades at $0.96 with a market cap of $263.72M and a P/E ratio of -7.92. AKBA moved +0.00% today. Year to date, AKBA is -40.14%; over the trailing twelve months it is -68.17%. Its 52-week range spans $0.81 to $4.08. Analyst consensus is strong buy with an average price target of $3.90. Rallies surfaces AKBA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are AKBA's key financials?

AKBA financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. AKBA recently traded at $0.96. Market cap is $263.72M. P/E ratio is -7.92. Revenue is $219.06M.

AKBA Key Metrics

Key financial metrics for AKBA
Metric	Value
Price	$0.96
Market Cap	$263.72M
P/E Ratio	-7.92
EPS	$-0.12
Dividend Yield	0.00%
52-Week High	$4.08
52-Week Low	$0.81
Volume	53.29K
Avg Volume	0
Revenue (TTM)	$219.06M
Net Income	$-29.67M
Gross Margin	79.63%

AKBA Analyst Consensus

5 analysts cover AKBA: 0 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $3.90.

Common questions about AKBA

What are AKBA's key financials?: AKBA financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. AKBA recently traded at $0.96. Market cap is $263.72M. P/E ratio is -7.92. Revenue is $219.06M.
Is AKBA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for AKBA. It does not provide personalized investment advice.